SAR421869

DRUG2 trials

Sponsors

Sanofi-Aventis Recherche & Developpement, Sanofi

Conditions

Retinitis PigmentosaUsher SyndromeUsher's syndrome

Phase 1

Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

TerminatedNCT01505062

SanofiRetinitis Pigmentosa, Usher Syndrome

Start: 2012-03-26End: 2019-08-16Updated: 2022-04-28

Phase 2

An open-label study to determine the long-term safety, tolerability and biological activity of SAR421869 in patients with Usher syndrome Type 1B

Active, not recruitingCTIS2024-513500-34-00

Sanofi-Aventis Recherche & DeveloppementUsher's syndrome

Start: 2015-11-09Target: 4Updated: 2024-09-12

Related Papers

Retinal Gene Therapy for Usher Syndrome: Current Developments, Challenges, and Perspectives

International Ophthalmology Clinics2021-09-2814 citations